The U.S. Food and Drug Administration (FDA) has granted approval of Novo Nordisk’s Norditropin® FlexPro® 30 mg/3.0 mL, a prefilled injection pen for patients with growth hormone-related disorders. The FlexPro® 30 mg/3.0 mL device complements the existing FlexPro® products.
“Novo Nordisk is committed to advancing growth hormone delivery devices with patients in mind,” said Eddie Williams, senior vice president, Biopharmaceuticals, Novo Nordisk. “This approval marks another option for patients who may need higher doses of treatment.”
Norditropin® FlexPro® is available in four different strengths in color-coded “pens.” Novo Nordisk plans to make Norditropin® FlexPro® 30 mg/3.0 mL available by April 2015.
Advertisement
SOURCE Novo Nordisk
